2 state attorneys general file suit over Trump move on association health plans

New York and Massachusetts will sue the Trump administration following the announced expansion of association health plans, arguing the move will invite “fraud, mismanagement and deception.”

"We will sue to safeguard the protections under the Affordable Care Act and ensure that all families and small businesses have access to quality, affordable healthcare," Attorneys General Barbara Underwood (New York) and Maura Healey (Massachusetts) said in a statement. "We believe the rule, as proposed, is unlawful and would lead to fewer critical consumer health protections."

Proponents of the plans, which do not have to meet regulations established by the Affordable Care Act (ACA), argue the regulation will decrease costs because the plans do not have to meet regulations established by the Affordable Care Act (ACA). Critics claim the move will destabilize the ACA insurance market by encouraging younger, healthier individuals to seek coverage elsewhere.

The Congressional Budget Office estimates four million people take advantage of association health plans.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.